+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of nipocalimab compared to placebo in adults with moderate to severe systemic lupus erythematosus SLE, a long-term autoimmune disease where the immune system attacks healthy tissues causing inflammation in various organs. This phase 3, randomized, double-blind study aims to determine how well nipocalimab works alongside standard care treatments in managing SLE symptoms and disease activity. Participants will receive either nipocalimab or placebo combined with standard care treatments during a 52-week double-blind period. After this, eligible participants from both groups can join an open-label extension where they will continue to receive nipocalimab until Week 156 or until the study intervention is stopped. This design allows comparison of nipocalimabs effects versus placebo and longer-term safety and effectiveness in an open-label setting. Throughout the study, participants undergo regular assessments including disease activity indexes, joint evaluations, and fatigue scores. Researchers will track the percentage of participants achieving a standard SLE response measure at Week 52 and monitor changes in oral glucocorticoid use, joint pain, and flare-free status. Safety and treatment adherence are closely monitored across study visits, with data collected up to 3 years for long-term evaluation.

Age: 18Years - 75YearsAll GendersPhase 3
272 locations
E

Actively Recruiting

Crohns disease is a long-term condition causing inflammation that can affect any part of the gut. This research aims to evaluate the safety and effectiveness of TAK-279 compared to a placebo in adults with moderately to severely active Crohns disease. The main goal is to find out if three different doses of TAK-279 can reduce bowel inflammation and ulcers after 12 weeks of treatment using endoscopy to assess the bowel. Participants will be randomly assigned to receive one of three doses of TAK-279 or a placebo capsule, taken orally. The treatment period lasts for 52 weeks, or 1 year. The study includes an initial induction phase with treatment assignment and a 4-week safety follow-up phase after completing treatment. The trial is conducted at multiple centers worldwide and involves about 268 participants. Participants will visit the study clinic 15 times during the study. During these visits, researchers will conduct endoscopies and use scores like the Simple Endoscopic Score for Crohns Disease SES-CD and the Crohns Disease Activity Index CDAI to measure inflammation and disease activity. Quality of life and fatigue will also be assessed using questionnaires. Safety and tolerability will be monitored throughout the study and during the follow-up period, with total participation lasting about 60 weeks.

Age: 18Years - 75YearsAll GendersPhase 2
201 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of induction therapy using Afimkibart also called RO7790121 in adults with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to determine whether this treatment can induce clinical remission and improve endoscopic response compared to placebo. The trial is led by Hoffmann-La Roche and focuses on participants aged 16 to 80 years who have an inadequate response or intolerance to other Crohns disease treatments. Participants are randomly assigned to one of two groups one group receives Afimkibart initially through intravenous infusion followed by subcutaneous injections, while the other group receives a placebo intravenous infusion followed by Afimkibart subcutaneous injections. The study follows a parallel design with double-blinding to compare the effects of these treatment approaches over a 12-week induction period. During the trial, participants will undergo assessments including Crohns Disease Activity Index scoring, endoscopic evaluations, and symptom tracking such as stool consistency, abdominal pain, and fatigue. Researchers will monitor clinical remission, symptomatic relief, and adverse events up to 30 weeks after baseline. Quality of life will be measured with questionnaires, and biomarker subgroups will be analyzed. The studys total duration extends through 2033, with key measurements taken at week 12.

Age: 16Years - 80YearsAll GendersPhase 3
208 locations
P

Actively Recruiting

Researchers are evaluating the effects of different doses of brivekimig compared to a placebo in adults with moderate to severe Crohns disease. This phase 2, randomized, double-blind study aims to assess the treatments impact on endoscopic response and remission. The trial includes participants who have not adequately responded to standard therapies. The study is sponsored by Sanofi and plans to enroll adults aged 18 to 75 years. Participants will be randomly assigned to receive one of two dosing regimens of brivekimig or a placebo, all administered by subcutaneous injection. The treatment period can last up to 158 weeks and includes an optional open-label long-term extension lasting up to 104 weeks for eligible participants. The study design includes three groups two experimental brivekimig dose regimens and one placebo group. Throughout the study, participants will undergo assessments to measure endoscopic response at week 16 and other clinical outcomes such as remission rates, symptom scores, serum drug levels, and safety monitoring for adverse events. Evaluations include Crohns Disease Activity Index scores, patient-reported outcomes, and endoscopic examinations up to week 52. The total duration of participation may be up to 168 weeks, with ongoing safety and efficacy monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
78 locations
C

Actively Recruiting

Researchers are evaluating a new combination of medicines, DSP107 and atezolizumab, compared to an existing treatment, fruquintinib, for adults with advanced microsatellite stable MSS colorectal cancer. This Phase 2b study focuses on patients whose cancer has progressed or who cannot tolerate standard therapies. The study aims to assess whether the new combination improves patient outcomes while monitoring safety and how the body processes these treatments. Participants will be randomly assigned to one of two groups. One group receives DSP107 intravenously on Days 1, 8, and 15, plus atezolizumab intravenously on Day 1 of each 28-day cycle. The other group takes fruquintinib orally once daily for 21 days, followed by 7 days off, in 28-day cycles. The treatment period can last up to 24 cycles, with adjustments made based on tolerance. After treatment, a safety follow-up of up to 90 days will occur, followed by long-term follow-up for up to five years. During the study, participants will have regular assessments including evaluations of overall survival, adverse events, heart function via ECG, blood pressure, pulse rate, quality of life, and immune response to DSP107. Participants keep dosing diaries if taking fruquintinib. The study includes screening lasting up to 28 days before treatment starts. Total participation time depends on treatment response and tolerability, with ongoing monitoring throughout and after the treatment phase.

Age: 18Years +All GendersPhase 2
18 locations
L

Actively Recruiting

This research aims to evaluate the long-term safety and tolerability of inhaled antifibrotic medications, specifically AP01, in participants who have previously completed Avalyn Pharma sponsored studies involving this treatment. The study focuses on individuals with progressive pulmonary fibrosis or idiopathic pulmonary fibrosis IPF, excluding IPF subjects from the US and Canada. The goal is to continue assessing the effects of AP01 over an extended period. Participants will receive 100 mg of inhaled pirfenidone solution AP01 twice daily using the eFlow Nebulizer System. The study includes a ScreeningBaseline Visit, an open-label Treatment Period where all participants receive AP01, and a Follow-upEnd of Study phone call approximately two weeks after the last dose. The dosing during the treatment period will be monitored with a paper diary and by collecting any unused medication. Throughout the study, participants will be assessed for long-term safety and tolerability outcomes, including changes in lung function measured by forced vital capacity FVC, disease stabilization, and quality of life. The trial is expected to last an average of six years, with evaluations continuing until the studys end. Participants will have regular monitoring and follow-up to track their progress and adherence to the treatment.

Age: 18Years +All GendersPhase 2
85 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of trimodulin as an additional treatment to the standard care for hospitalized adult patients with severe community-acquired pneumonia sCAP who require invasive mechanical ventilation IMV. This phase III, randomized, placebo-controlled, and double-blind trial aims to compare trimodulin plus standard care against placebo plus standard care. The study also includes assessments of trimodulins detailed pharmacokinetic and pharmacodynamic properties. Participants are randomly assigned in a 11 ratio to receive either trimodulin or a placebo, both given intravenously once daily for five consecutive days alongside standard care. Following treatment, participants enter a follow-up phase lasting up to 23 days, with an end-of-follow-up visit or phone call on day 29. For those still hospitalized after day 29, extended follow-up continues until discharge or day 90, and a closing visit or call is conducted around day 91. During the study, participants will undergo multiple assessments including evaluation of mortality rates up to 28 and 90 days, clinical cure rates, organ failure scores, ventilator use, oxygen supply, ICU and hospital stays, readmission rates, adverse events, and changes in vital signs and laboratory parameters. Safety monitoring includes electrocardiograms and tracking of adverse events throughout the treatment and follow-up periods. The total participation duration can extend up to approximately three months depending on hospital discharge timing.

Age: 18Years +All GendersPhase 3
170 locations
P

Actively Recruiting

This research is focused on patients with acute severe brain injuries, such as those caused by stroke, traumatic injury, or oxygen loss after cardiac arrest, who require mechanical ventilation. It evaluates whether giving a single dose of a commonly used antibiotic soon after intubation can prevent infections in the airways and lungs, known as pneumonia, which is a common complication in these patients. The study aims to improve survival and recovery chances by preventing these infections early. Participants are randomly assigned to receive either a single intravenous dose of 2 grams of ceftriaxone diluted in at least 200 mL of 0.9% sodium chloride or a placebo an intravenous infusion of 0.9% sodium chloride without ceftriaxone shortly after intubation. This is a double-blind trial, meaning neither participants nor researchers know who receives the antibiotic or placebo. The treatment is given once shortly after the breathing tube is inserted. During the study, participants will be monitored for 90 days to measure overall survival and for 180 days to assess functional outcomes related to brain injury recovery. Researchers will collect data on survival rates, neurological function, length of mechanical ventilation, need for reintubation or tracheostomy, and other related health measures. The study also monitors safety and evaluates if antibiotic use affects outcomes and antibiotic resistance over time.

Age: 18Years +All GendersPhase 3
29 locations
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations

1-10 of 13

1